Expression and diagnostic relevance of heat shock protein 90 and signal transducer and activator of transcription 3 in malignant pheochromocytoma

Journal of Clinical Pathology

Volumn 66, Issue 4, 2013, Pages 286-290

  Xu, Yunze ^a   Qi, Yicheng ^a   Rui, Wenbin ^a   Zhu, Yu ^a   Zhang, Chongyu ^a   Zhao, Juping ^a   Wei, Qing ^a   Wu, Yuxuan ^a   Shen, Zhoujun ^a   Ning, Guang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN 90; STAT3 PROTEIN;

ADOLESCENT; ADRENALECTOMY; ADULT; AGED; ARTICLE; CHILD; DIAGNOSTIC VALUE; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT PHEOCHROMOCYTOMA; ONSET AGE; PHEOCHROMOCYTOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; TUMOR LOCALIZATION; TUMOR VOLUME; WESTERN BLOTTING;

ADRENAL GLAND NEOPLASMS; ADULT; AGED; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PHEOCHROMOCYTOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; STAT3 TRANSCRIPTION FACTOR; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84875229184     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-201134     Document Type: Article

References (28)

1. Lenders JW, Eisenhofer G, Mannelli M, et al. Phaeochromocytoma. Lancet 2005;366:665-75.
2. Edstrom EE, Hjelm SAL, Hoog A, et al. The management of benign and malignant pheochromocytoma and abdominal paraganglioma. Eur J Surg Oncol 2003;29:278-83.
3. Eisenhofer G, Bornstein SR, Brouwers FM, et al. Malignant pheochromocytoma: Current status and initiatives for future progress. Endocr Relat Cancer 2004;11:423-36.
4. Chrisoulidou A, Kaltsas G, Ilias I, et al. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 2007;14:569-85.
5. Neckers L, Ivy SP. Heat shock protein 90. Curr Opin Oncol 2003;15:419-24.
6. Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: The story unfolds. Expert Opin Biol Ther 2002;2:3-24.
7. Darnell JE Jr. STATs and gene regulation. Science 1997;277:1630-5.
8. Prinsloo E, Kramer AH, Edkins AL, et al. STAT3 interacts directly with Hsp90. IUBMB Life 2012;64:266-73.
9. Bowman T, Garcia R, Turkson J, et al. STATs in oncogenesis. Oncogene 2000;19:2474-88.
10. Ayala-Ramirez M, Feng L, Johnson MM, et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: Primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab 2011;96:717-25.
11. Ohji H, Sasagawa I, Iciyanagi O, et al. Tumour angiogenesis and Ki-67 expression in phaeochromocytoma. BJU Int 2001;87:381-5.
12. Feng F, Zhu Y, Wang X, et al. Predictive factors for malignant pheochromocytoma: Analysis of 136 patients. J Urol 2011;185:1583-90.
13. Qi Y, Su T, Zhang X, et al. Gene expression profiles of phaeochromocytomas with ERBB2 overexpression reveal a new molecular mechanism tumourigenicity. Clin Endocrinol (Oxf) 2012;77:399-406.
14. Zhu Y, He HC, Yuan F, et al. Heparanase-1 and Cyclooxygenase-2: Prognostic indicators of malignancy in pheochromocytomas. Endocrine 2010;38:93-9.
15. Klingler HC, Klingler PJ, Martin JK Jr, et al. Pheochromocytoma. Urology 2001;57:1025-32.
16. Khalil AA, Kabapy NF, Deraz SF, et al. Heat shock proteins in oncology: Diagnostic biomarkers or therapeutic targets? Biochim Biophys Acta 2011;1816:89-104.
17. Schmitt E, Gehrmann M, Brunet M, et al. Intracellular and extracellular functions of heat shock proteins: Repercussions in cancer therapy. J Leukoc Biol 2007;81:15-27.
18. Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood) 2003;228:111-33.
19. Trepel J, Mollapour M, Giaccone G, et al. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010;10:537-49.
20. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-72.
21. Chatterjee M, Jain S, Stuhmer T, et al. STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival. Blood 2007;109:720-8.
22. Boltze C, Mundschenk J, Unger N, et al. Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma. J Clin Endocrinol Metab 2003;88:4280-6.
23. Ehrlich ES, Wang T, Luo K, et al. Regulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligase. Proc Natl Acad Sci USA 2009;106:20330-5.
24. Khong T, Spencer A. Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma. Mol Cancer Ther 2011;10:1909-17.
25. Powers MV, Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 2006;13(Suppl 1): S125-35.
26. Fletcher S, Drewry JA, Shahani VM, et al. Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. Biochem Cell Biol 2009;87:825-33.
27. Bromberg J. Stat proteins and oncogenesis. J Clin Invest 2002;109:1139-42.
28. Sato N, Yamamoto T, Sekine Y, et al. Involvement of heat-shock protein 90 in the interleukin-6-mediated signaling pathway through STAT3. Biochem Biophys Res Commun 2003;300:847-52.